The week in industry: CAD$10 Million awarded to develop novel cancer therapies
This week: bluebird bio gains first approval for their gene therapy ZYNTEGLO™, the first and only drug for episodic cluster headaches approved by US FDA and more companies join the Quantum Leap project to improve novel intracellular delivery technology.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>